Immune checkpoint inhibitors (ICIs), targeting inhibitory receptors such as Programmed cell death protein 1 (PD-1), Programmed death-ligand 1 (PD-L1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have revolutionised cancer therapy [1]. Here, PDCD1 is linked to cancer.